Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.43 |
| ▸ | HTR2C | P28335 | 13/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906416 | 0.86 | BRD4 (0.43) | HTR2AHTR2C | |
| SCHEMBL4900097 | 0.84 | PIP4K2A (0.44) | — | |
| SCHEMBL4914131 | 0.81 | LMNA (0.41) | — | |
| SCHEMBL4906051 | 0.81 | GSK3B (0.47) | HTR2AHTR2CCDK2 | |
| SCHEMBL4905855 | 0.81 | BPTF (0.46) | HTR2AHTR2C | |
| SCHEMBL4910787 | 0.80 | MAPT (0.50) | HTR2AHTR2C | |
| SCHEMBL4911346 | 0.80 | BRD4 (0.42) | HTR2AHTR2C | |
| SCHEMBL4907250 | 0.79 | BRD4 (0.45) | HTR2AHTR2CCYP17A1 | |
| SCHEMBL4910964 | 0.77 | KDM1A (0.41) | CDK2PDGFRBPDGFRA | |
| SCHEMBL4908312 | 0.76 | HAVCR2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | claimed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| WO-2006060762-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR2A, HTR3A | HTR2A 2/4885HTR2C 5/4885CYP17A1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.